Mayo Clinic Cancer Center | Strategic Alliance Partners

Latest from Mayo Clinic Cancer Center

Ovarian Suppression with GnRH Agonists Can Aid Fertility Preservation in Breast Cancer

May 12, 2022

Treatment regimens that include ovarian suppression with a gonadotropin-releasing hormone agonist have gained momentum in recent years as a potential solution to address treatment-related early menopause for women with breast cancer.

Abemaciclib Plus Endocrine Therapy Elicits Efficacy in High-Risk, HR+ Early Breast Cancer Regardless of Menopausal Status

May 10, 2022

The addition of abemaciclib to endocrine therapy improved invasive disease-free survival and distant relapse-free survival vs endocrine therapy alone in patients with high-risk, hormone receptor–positive, HER2-negative, early-stage breast cancer, irrespective of menopausal status.

Tafasitamab/Lenalidomide Improves OS Over Other Options in Retrospective Relapsed/Refractory DLBCL

December 11, 2021

The combination of tafasitamab and lenalidomide prolonged median overall survival compared with other standard options for autologous stem cell transplant-ineligible patients with relapsed/refractory diffuse large B-cell lymphoma.

Management Strategies Shift Across NSCLC, Small Cell Lung Cancer, and Mesothelioma

October 07, 2021

As novel therapies, new treatment strategies, and ongoing clinical trials continue to steer the path forward in lung cancer, treatment patterns for patients with non–small cell lung cancer, small cell lung cancer, and mesothelioma are continuing to evolve.